Pediatric Pharmacology Research Unit

儿科药理研究室

• 批准号: 6855804
• 负责人: JACOB V ARANDA
• 金额: $ 37.57万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-07 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6855804
• 关键词: GABA receptor; age difference; apnea; asthma; autism; blood brain barrier; cerebral ischemia /hypoxia; child (0-11); clinical research; clinical trials; cooperative study; diagnosis design /evaluation; dosage; drug adverse effect; drug delivery systems; drug metabolism; drug screening /evaluation; embryo /fetus pharmacology; human subject; human therapy evaluation; infant human (0-1 year); nanotechnology; newborn human (0-6 weeks); pain; patient oriented research; pediatric pharmacology; pediatrics; pharmacogenetics; pharmacokinetics; positron emission tomography; prenatal growth disorder; proteomics; statistics /biometry; therapy design /development

DESCRIPTION (provided by applicant): The overarching aim of this proposal is to ensure continuation of the Neonatal and Pediatric Pharmacology Research Unit (PPRU) at the Children's Hospital of Michigan and Wayne State University (WSU) The WSU PPRU has conducted more than 40 multicenter and single site trials and has led the evaluation of drugs such as the multicenter tiral on the new formulation of intravenous ibuprofen for early closure of patent ductus artriousus in the preterm newborn. WSU PPRU ranked among the top 6 sites for subject enrollment. In addition, studies on aberrant development of serotonin biosynthesis in autistic children using PET scanning and identification of the phenotypic variants of serotonin metabolism have led to the ongoing evaluation of buspirone in drug therapy of autism. The demonstration of the role of NFKb in the gene expression of inflammatory mediators including the cyclo-oxygenases identified a target focus for drug intervention. The specific aims include: 1) the conduct of studies to generate requisite data on bioavailability, formulations, drug metabolism, pharmacokinetics, pharmacodynamics, safety, and effectiveness of new molecular entities and drugs currently used and are potentially used in the unborn fetus, newborn and children. 2) To determine the ontogeny of GABA receptors and to develop innovative pharmacotherapies of neonatal and childhood diseases such as neonatal apnea, neonatal hypoxic-ischemic encephalopathy and autism 3) To apply nanotechnology and use of dendrimers in targeted drug delivery and to develop novel formulations to modulate drug transfer across the blood brain barrier during development 4) to determine the validity of non-invasive cry analyses technique as surrogate pharmacodynamic measure in neonatal pain and non-verbal children 5) to develop novel drug therapies for fetuses with intrauterine growth retardation. 6)To determine the role of B2AR gene polymorphism in beta adrenergic response in asthmatic children and to provide a clinical milieu for the application of pharmacogenomics and proteomic technology leading to individualized pediatric pharmacotherapy and 7) to provide educational and training programs in pediatric pharmacology. Taken collectively, these initiatives will advance rational, safe, effective and cost beneficial drug therapies in the fetus, newborn and children.

描述（由申请人提供）： 该提案的总体目的是确保在密歇根州和韦恩州立大学（WSU）的儿童医院（WSU PPRU）继续进行40多个多中心和单个现场试验，并导致了诸如新的Intraver tiraus tiral tiral of tiral tiral of in triral of tiral tiral of tiral tiral of tiral tiral of tiral tiral trab ppru，在密歇根州和韦恩州立大学（WSU PPRU）的儿童医院（WSU PPRU）上继续延续了新型多中心和单个现场试验。早产的ductus artriousus。 WSU PPRU在受试者注册的前6个地点中排名。此外，使用PET扫描和鉴定5-羟色胺代谢的表型变异的自闭症儿童中羟色胺生物合成异常的研究已导致对自闭症药物治疗中胰蛋白酶的持续评估。 NFKB在炎症介质（包括环氧酶）中的作用的证明确定了药物干预的靶向重点。具体目的包括：1）进行研究，以生成有关生物利用度，配方，药物代谢，药代动力学，药效学，安全性，安全性和有效性的必要数据，并可能用于未出生的胎儿，新生儿，新生儿和儿童。 2）确定GABA受体的个体发育，并开发新生儿和儿童期疾病的创新药物治疗，例如新生儿呼吸呼吸暂停，新生儿缺氧 - 缺氧性疾病和自闭症3）以在纳米技术和使用新颖的药物跨度的范围内使用纳米技术和使用范围的药物的繁殖力，以在目标药物转移方面进行跨性别的药物转移，以形成跨性别的药物培训，以改造药物的培训，并在目标药物范围内进行跨性别的培训，并在范围内进行跨性别的培训。非侵入性哭泣将技术分析为新生儿疼痛和非语言儿童的替代药效学指标5）开发新的药物疗法，用于胎儿内生长迟钝的胎儿。 6）确定B2AR基因多态性在哮喘儿童中的β肾上腺素能反应中的作用，并提供临床环境，以应用药物基因组学和蛋白质组学技术，从而实现个性化的儿科药物治疗和7））提供了儿科药理学中的教育和培训计划。这些举措共同考虑了胎儿，新生儿和儿童的理性，安全，有效和成本有益的药物疗法。